Host-directed therapies for parasitic diseases

Future Med Chem. 2019 Aug;11(15):1999-2018. doi: 10.4155/fmc-2018-0439. Epub 2019 Aug 8.

Abstract

Parasitic infections are responsible for significant morbidity and mortality throughout the world. Management strategies rely primarily on antiparasitic drugs that have side effects and risk of drug resistance. Therefore, novel strategies are needed for treatment of parasitic infections. Host-directed therapy (HDT) is a viable alternative, which targets host pathways responsible for parasite invasion/survival/pathogenicity. Recent innovative combinations of genomics, proteomics and computational biology approaches have led to discovery of several host pathways that could be promising targets for HDT for treating parasitic infections. Herein, we review major advances in HDT for parasitic disease with regard to core regulatory pathways and their interactions.

Keywords: cellular therapy; immunopathology; metabolic pathways.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Cannabinoids / pharmacology
  • Cannabinoids / therapeutic use
  • Chagas Disease / drug therapy
  • Chagas Disease / pathology
  • Humans
  • Leishmaniasis / drug therapy
  • Leishmaniasis / immunology
  • Leishmaniasis / pathology
  • Parasitic Diseases / drug therapy*
  • Parasitic Diseases / immunology
  • Parasitic Diseases / pathology
  • T-Lymphocytes / cytology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Toxoplasmosis / drug therapy
  • Toxoplasmosis / pathology
  • Trypanosoma cruzi / drug effects
  • Trypanosoma cruzi / physiology

Substances

  • Anti-Infective Agents
  • Antibodies, Monoclonal
  • Cannabinoids